High-content single-cell drug screening with phosphospecific flow cytometry.
Drug screening is often limited to cell-free assays involving purified enzymes, but it is arguably best applied against systems that represent disease states or complex physiological cellular networks. Here, we describe a high-content, cell-based drug discovery platform based on phosphospecific flow cytometry, or phosphoflow, that enabled screening for inhibitors against multiple endogenous kinase signaling pathways in heterogeneous primary cell populations at the single-cell level. From a library of small-molecule natural products, we identified pathway-selective inhibitors of Jak-Stat and MAP kinase signaling. Dose-response experiments in primary cells confirmed pathway selectivity, but importantly also revealed differential inhibition of cell types and new druggability trends across multiple compounds. Lead compound selectivity was confirmed in vivo in mice. Phosphoflow therefore provides a unique platform that can be applied throughout the drug discovery process, from early compound screening to in vivo testing and clinical monitoring of drug efficacy.
D000818:Animals; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D053612:Janus Kinases / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010758:Phosphorus / Q000032:analysis*; D050791:STAT Transcription Factors / Q000378:metabolism; D012680:Sensitivity and Specificity; D015398:Signal Transduction
D050791:STAT Transcription Factors; D010758:Phosphorus; D053612:Janus Kinases; D020928:Mitogen-Activated Protein Kinases